Clinical trial
Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
NCT00474760 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00474760 |
|---|---|
| Title | Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors |
| Official title | Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sarcoma, Ewing's |
| Intervention type | Drug |
| Interventions | CP-751, 871 |
| Enrollment | 65 |
| Start date | Aug 1, 2005 |
| Primary completion | Jan 1, 2011 |
| Completion | Oct 1, 2012 |
| First posted | May 17, 2007 |
| Last update posted | Dec 17, 2013 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: